Importance The optimal duration of dual antiplatelet therapy (DAPT) for older adults after
percutaneous coronary intervention (PCI) is uncertain because they are simultaneously at …

Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …

Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual
antiplatelet therapy [DAPT] or dual pathway inhibition [DPI]) are recommended for …

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of
the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in …

Abbreviation of the duration of dual antiplatelet therapy (DAPT)(one or three months) has
been recently proposed, especially for high bleeding risk patients, after percutaneous …

Patients≥ 75 years of age account for about one third of hospitalizations for acute coronary
syndromes (ACS). Since the latest European Society of Cardiology guidelines recommend …

Background Clopidogrel was superior to aspirin monotherapy in secondary prevention after
percutaneous coronary intervention (PCI). Objectives The purpose of this study was to …

Importance Dual antiplatelet therapy (DAPT) appears to be an effective treatment option for
minor (nondisabling) acute ischemic stroke. This conclusion is based on trials that include …

Background Previous studies have investigated a 1 to 6-month short dual antiplatelet
therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting …

Ticagrelor is a platelet P2Y12 receptor inhibitor approved for use in patients with acute
coronary syndromes, coronary artery disease, and low‐moderate risk acute ischemic stroke …